

ORIGINAL RESEARCH

Primary Care Providers' Needs and Preferences for Information about Colorectal Cancer Survivorship Care

Talya Salz, PhD, Kevin C. Oeffinger, MD, Peter R. Lewis, MD, Robert L. Williams, MD, Robert L. Rhyne, MD, and Mark W. Yeazel, MD

Background: The Institute of Medicine (IOM) proposed that cancer survivors and their primary care providers (PCPs) should receive survivorship care plans to inform ongoing care. We aimed to determine PCPs' preferences for the content of survivorship care plans for colorectal cancer (CRC) survivors.

Methods: PCPs in 3 practice-based research networks completed a survey regarding 45 topics of CRC information based on the IOM's survivorship care plan framework.

Results: One hundred fifty-six PCPs completed the survey. For 35 topics (78%), at least half of respondents felt the topic was very important. Most PCPs reported receiving too little information about problems with chemotherapy (68%) or radiation (60%) and whether the oncologist intended to monitor for other cancers (71%). PCPs widely agreed that they do not have enough information about increased risk of second CRCs, other cancers, and other diseases (78%); long-term effects of chemotherapy (73%) and radiation (67%); and genetic counseling (83%).

Conclusions: PCPs endorse the IOM's survivorship care plan framework as relevant and often report needing more information. Survivorship care plans may provide important information to PCPs by communicating patients' cancer histories and making recommendations regarding which aspects of care should be provided by the oncologist or the PCP. (J Am Board Fam Med 2012;25:635–651.)

Keywords: Cancer, Colorectal Cancer, Practice-based Research, Practice-based Research Networks, Primary Health Care, Survivors

Primary care providers (PCPs) are critical to cancer survivors' health, delivering general and preventive care and managing multiple conditions that may be unrelated to the cancer. However, PCPs may not

feel confident in their ability to care for cancer survivors. They may lack relevant information about their patients' cancer treatment, the intended coordination of care with the oncologist, or general survivorship issues. Survivorship care plans are an intervention that can inform PCPs about the recommended care of cancer survivors. Proposed by the Institute of Medicine (IOM) in their report about cancer survivorship, *From Cancer Patient to Cancer Survivor: Lost in Transition*, survivorship care plans are documents that summarize a survivor's treatment history and recommended ongoing care.¹ The authors of the IOM report recommend that oncologists give patients a survivorship care plan that they can then share with their PCPs. The use of survivorship care plans may benefit PCPs by promoting personalized and coordinated cancer survivorship care.

The IOM report enumerates detailed information to include in a survivorship care plan. The

This article was externally peer reviewed.

Submitted 13 March 2012; revised 13 June 2012; accepted 18 June 2012.

From the Memorial Sloan-Kettering Cancer Center (TS, KCO); Penn State College of Medicine, State College, PA (PRL); University of New Mexico School of Medicine (RLW, RLR); and University of Minnesota (MWY).

Funding: This work was supported by a research grant from the National Cancer Institute (R03-CA-144682-01).

Prior presentation: Parts of this work were previously presented at the Minnesota Academy of Family Practice 2011 Annual Meeting; the American Society of Clinical Oncology 2011 Annual Meeting; the Agency for Healthcare Research and Quality's Practice-Based Research Network 2011 Annual Meeting; and the North American Primary Care Research Group 2011 Annual Meeting.

Conflict of interest: none declared.

Corresponding author: Talya Salz, MSKCC, Epidemiology and Biostatistics, 307 E 63rd St, 2nd Floor, New York, NY 10065 (E-mail: salzt@mskcc.org).

information generally falls into the following categories: a summary of the survivor's diagnosis and treatment, recommendations for ongoing care, and a listing of practical survivorship-related resources (such as support groups). As recipients of survivorship care plans, PCPs may or may not value all of this information. Also, PCPs may wish to receive additional information that is not suggested for inclusion in survivorship care plans. To maximize the usefulness of survivorship care plans for cancer survivors, we must better understand the perspectives of PCPs and refine the IOM framework for a survivorship care plan accordingly.

Survivorship care plans must ultimately be tailored to a specific cancer because not all categories of information in the IOM framework (such as descriptions of hormone receptor status, gene therapy, and familial risk) apply to all cancers. Furthermore, PCPs' needs and preferences for information may vary by disease site. Therefore, we focused our study on a single cancer: colorectal cancer (CRC). The involvement of PCPs is particularly important for CRC survivors, who comprise a large group with documented primary care needs. More than a million people are alive in the United States with a diagnosis of CRC, and with improved early detection and treatment, most live beyond the period of active cancer treatment.^{2,3} Although CRC survivors typically do not experience severe consequences of their cancer and therapy after the completion of treatment (distinguishing them from survivors of many other cancers), they do face ongoing medical and psychological challenges that may be addressed by a PCP.⁴⁻⁷ CRC survivors also receive poorer quality noncancer care, including less frequent receipt of general preventive health care, compared with individuals who do not have cancer.⁸ CRC survivors who visit a PCP receive more preventive care compared with survivors who do not visit a PCP.^{9,10} Preventive care is especially important in this population because the lifestyle risk factors for CRC (such as obesity) may also contribute to cardiovascular disease and other serious health problems unrelated to the cancer. To inform the refinement of the IOM framework for CRC, we conducted a survey of PCPs who have cared for CRC survivors to identify their informational needs and preferences for the content and delivery of CRC survivorship care plans.

Methods

Design and Sample

We implemented a cross-sectional survey of PCPs (physicians, physician assistants, and nurse practitioners) from a sample of 3 practice-based research networks (PBRNs) chosen to provide geographic and practice-setting diversity: one each in Minnesota, Pennsylvania, and New Mexico. PBRNs are networks of clinical practices that involve academic and community clinicians engaged in research on primary care. The Minnesota Academy of Family Physicians Research Network includes providers in all counties of Minnesota among 110 practices, 12% of which are academic practices. The Penn State Ambulatory Research Network encompasses 20 practices in both community and academic settings (86% academic) in Central Pennsylvania. None are private practice. Research Involving Outpatient Settings Network includes providers in community health centers, Indian Health Services, and academic settings in 70 practices throughout New Mexico. Approximately one third are academic practices.

All nonpediatrician PCPs at each network were invited to participate in an anonymous online survey. Invitations to participate were sent via E-mail between July 2010 and April 2011. The invitations explained the study topic, that participation and responses were anonymous, and that the survey was deemed exempt from institutional review board review at their affiliated institution. Additional E-mailed invitations were sent to all participants between 3 and 6 times over a period of 2 to 6 months. We attempted to balance the proportion of respondents at each site and therefore extended the enrollment time and increased the number of invitations for sites that recruited more slowly. Interested PCPs could take the survey using log-in codes included in the E-mailed invitation. The survey began with questions screening for eligibility; PCPs who reported that they provided primary care and cared for at least one CRC survivor in their practice during the past year were deemed eligible to participate and automatically continued on to the survey itself.

Instrument

We designed a self-administered, Internet-based questionnaire assessing PCPs' opinions and informational needs for survivorship care plans (see the

Appendix for the questionnaire). Using the IOM's framework for a survivorship care plan, we created 45 topics that were potentially relevant to CRC survivors. These topics fall into the categories of (1) patient-specific information about diagnosis, treatment, coordination of care, and medical reports, and (2) general CRC survivorship information. The questionnaire asked providers to consider the care of patients who completed active curative treatment for CRC and had no evidence of disease. The questionnaire elicited providers' opinions about (1) the importance of each topic, (2) whether the provider typically had enough information about this topic, and (3) preferences for the format and delivery of this information. For the items assessing importance, response options were "not important," "somewhat important," "very important," and "undecided." For the items regarding having enough information, the response options were "not enough," "just the right amount," "too much," and "it varies too much to say." The questionnaire assessed past receipt of categories of information in the IOM framework (summary of diagnosis, summary of treatment, recommendations of ongoing care from the PCP, and information about what aspects of care the PCP and oncology provider are responsible for). For those who received this information, we asked how useful it was; for those who did not, we asked how useful it would be. The questionnaire included open-ended items pertaining to information that providers needed and questions about provider and practice characteristics. The Web Survey Core at Memorial Sloan-Kettering Cancer Center (<http://www.mskcc.org/mskcc/html/90103.cfm>) implemented the online questionnaire via a secure and private platform. All data from the survey were received anonymously by Memorial Sloan-Kettering Cancer Center for analysis.

Analyses

We used descriptive analyses to report preferences and information needs. Participants with missing data were excluded on a question-by-question basis, and those participants missing more than 50% of all responses were excluded from all analyses. For brevity, we presented only the percentage of respondents who reported each topic was very important to know and the percentage of respondents

Table 1. Demographic and Practice Characteristics of Study Sample (N = 156)

	No. (%)
Practice-based research network	
Minnesota Academy of Family Practice	43 (28)
Penn State Ambulatory Research Network	55 (35)
Research Involving Outpatient Settings Network	58 (37)
Male Gender	90 (58)
Profession	
Physician	
Family medicine	115 (74)
Internal medicine*	20 (13)
No board certification reported	2 (1)
Nurse practitioner	13 (8)
Physician assistant	6 (4)
Electronic medical records used in practice	134 (86)
	Mean (SD)
Age (years)	50 (9)
Year training completed	1989 (10)
Cancer patients [†] seen during last year	20 (30)
Colorectal cancer patients [†] seen during last year	3 (4)
Survivors [‡] of any cancer seen during last year	44 (67)
Survivors [‡] of colorectal cancer survivors seen during last year	6 (9)

*One family physician was also board certified in internal medicine.

[†]"Patient" refers to people currently undergoing treatment. [‡]"Survivor" refers to those who completed treatment.

who felt they typically do not have enough information about the topic. We categorized physician specialty based on reported board certification. Physicians who reported multiple specialties were conservatively categorized as belonging to the more common specialty. Responses to open-ended items were grouped into categories and reported descriptively.

Results

Sample

Of the 409 PCPs who were invited to participate, 191 logged into the survey (47%). Seventeen participants subsequently were found to be ineligible, and 18 participants were excluded because they completed less than 50% of the survey, resulting in 156 participants in the analytic sample (Table 1). One hundred thirty-seven participants (88%) were physicians; 73% of physicians were family physicians. Because of the high proportion of family

physicians, we compared their characteristics with those of the remaining respondents as a group. Family physicians were more likely to be men, were older, and completed training earlier than the remainder of the sample (data not shown). The distribution of provider types in our sample was not statistically different from that of the 3 networks, and we were unable to compare other demographic characteristics of our sample to the 3 networks. The mean reported number of CRC patients and survivors (ie, those who completed treatment) seen by respondents during the past year was 2.8 (standard deviation, 4.40) and 5.5 (standard deviation, 8.89), respectively.

Importance of Topics in IOM Framework

We categorized the 45 topics included in the IOM framework as patient-specific ($n = 34$) or general ($n = 11$), as shown in Tables 2 and 3. Across the 34 patient-specific topics, 71% (24) were deemed very important to know by at least 50% of respondents (Table 2). Cancer characteristics (site, stage, grade, and pathology) were deemed important by the majority of participants (60%–92%). Similarly, details about treatment (surgery, chemotherapy, and radiation) were deemed very important by at least 50% of participants, except for the date of completion of chemotherapy, the name and dose of chemotherapy drugs, and the dose of radiation. A substantial minority (37%–44%) indicated that information about other treatments provided, such as nutritional and psychosocial services, were very important to know. Ninety-eight percent of respondents felt that knowing whether the oncologist intended to monitor for recurrence and second CRCs was very important, and 90% reported that knowing whether the oncology provider intended to monitor for cancer at other sites (eg, subsequent breast cancer) was very important. Twenty-four of the 36 patient-specific topics (67%) were deemed important or very important by 95% of respondents or more. Only 2 topics were considered unimportant by more than 20% of respondents: dose of chemotherapy (48%) and dose of radiation (36%) (data not shown).

For the 11 topics that are generalizable to all CRC survivors, at least 64% of respondents endorsed each topic as very important (Table 3). Ninety-eight percent felt knowing the schedule of recommended CRC surveillance was very important, and 98% felt that knowing increased

risks for second CRCs, other cancers, and other diseases was very important. Fewer than 2% of respondents deemed each of the 11 topics unimportant. For each patient-specific or more generalized topic for which fewer than half of respondents deemed the topic very important, between 50% and 97% of respondents deemed the topic either somewhat important or very important (data not shown).

Need for Information about Topics in the IOM Framework

For patient-specific information, a substantial proportion of respondents reported typically not receiving enough information about their patient's diagnosis and treatment across all categories. The most widely endorsed topics for which respondents needed more information were knowing the reason for terminating chemotherapy (60%), whether there were any problems with chemotherapy (67%) or radiation therapy (60%), and whether complementary services were provided during treatment, including psychosocial (66%), nutritional (66%), and other (63%) supportive services. Seventy percent felt they typically did not have enough information about whether the oncologist intended to monitor the patient for cancers at other sites. A substantial minority of PCPs reported not having enough information about key clinical aspects of a cancer diagnosis, such as stage (40%) and grade (44%). Fewer than 5% of respondents felt they had too much information about each topic, with the exception of dose of chemotherapy and dose of radiation, for which 5% and 6% of respondents, respectively, felt they had too much information (data not shown).

There was a broader consensus that providers typically do not have enough information about more general issues affecting CRC survivors (ie, information that does not pertain to individual patients). At least half of all respondents reported needing more information about each general topic. Eighty-three percent typically wanted more information about genetic counseling and testing to identify high-risk individuals, whereas 78% typically needed more information about increased risks for second CRCs, other cancers, and other diseases. None of the respondents felt they had received too much information about CRC survivorship issues.

Table 2. Primary Care Physicians' Perspectives Regarding Information about Individual Colorectal Cancer Survivors' Diagnosis and Treatment Characteristics

Topic*	Very Important To Know	Not Enough Information
Diagnosis		
Stage of the patient's disease	143 (92)	63 (40)
Grade of the patient's disease	122 (78)	68 (44)
Site of the patient's disease (colon or rectum)	113 (73)	34 (22)
Relevant pathology of the patient's disease	104 (67)	64 (42)
Where the patient received treatment	93 (60)	38 (24)
Method of diagnosis	76 (49)	36 (23)
Surgery		
Whether patient had surgery	144 (92)	15 (10)
Any lingering effects of surgery	140 (90)	84 (55)
What the patient's anatomy is after surgery	126 (81)	97 (63)
If there were surgical complications	108 (69)	87 (56)
Date of the patient's surgery	89 (57)	32 (21)
Chemotherapy		
Whether patient had chemotherapy	147 (94)	28 (18)
Reason for terminating chemotherapy	123 (79)	93 (60)
Whether there were problems with chemotherapy	120 (77)	104 (68)
Contact information for the doctor who administered chemotherapy	96 (62)	66 (42)
Name of each chemotherapy drug administered	56 (36)	67 (43)
Dates each regimen of chemotherapy was completed	43 (28)	73 (47)
Dose of each chemotherapy drug administered	8 (5)	71 (46)
Radiation		
Whether patient had radiation therapy	146 (94)	26 (17)
Whether there were problems with radiation therapy	128 (82)	93 (60)
Reason for terminating radiation therapy	111 (72)	87 (56)
Location where radiation was administered	97 (62)	69 (45)
Contact information for the doctor who administered radiation therapy	86 (55)	62 (40)
Date radiation therapy was completed	85 (54)	61 (39)
Dose of radiation	25 (16)	64 (41)
Other aspects of treatment		
Whether patient was hospitalized for complications during treatment	109 (70)	76 (49)
Whether psychosocial services were provided during treatment	69 (44)	103 (66)
Whether patient was in a clinical trial	63 (40)	87 (56)
Whether other supportive services were provided during treatment	59 (38)	99 (63)
Whether nutritional services were provided during treatment	58 (37)	103 (66)
Coordination of care		
Whether cancer care provider(s) intend(s) to monitor the patient for recurrences and second primaries	153 (98)	90 (58)
Whether cancer care provider(s) intend(s) to monitor the patient for cancers at other sites	141 (90)	109 (71)
Medical reports		
Pathology report	106 (68)	71 (46)
Operative report	73 (47)	62 (40)

Values provided as n (%).

*Adapted from Institute of Medicine Report.¹

Additional Topics of Importance

For the open-ended items asking respondents to report additional needed information, the most commonly listed topics were the impact of the cancer on the family

and psychological status of the patient; each topic was mentioned 17 times. Also commonly reported as lacking were patient-specific information about prognosis (9 comments) and comorbidities (7 comments). Providers

Table 3. Primary Care Physicians' Perspectives Regarding Colorectal Cancer Survivorship Issues

Topic*	Very Important to Know	Not Enough Information
Any increased risks for second colorectal cancers, other cancers, and other diseases	153 (98)	122 (78)
The schedule of recommended colorectal cancer surveillance	153 (98)	79 (51)
Possible signs of recurrence and second tumors	145 (93)	93 (60)
The schedule of recommended screenings for noncolorectal cancers	139 (89)	85 (54)
Chemoprevention strategies for secondary prevention (eg, tamoxifen in women at high risk for breast cancer)	135 (87)	112 (72)
The possible long-term risks and complications from radiation therapy	135 (87)	104 (67)
The possible long-term risks and complications from chemotherapy	131 (85)	114 (73)
Other types of follow-up care providers that may be needed (eg, rehabilitation, fertility, psychology)	124 (79)	111 (71)
Genetic counseling and testing to identify high-risk individuals who could benefit from more comprehensive cancer surveillance	122 (78)	129 (83)
Possible effects of cancer on marital/partner relationship, sexual functioning, work, parenting, and future needs for psychosocial support	117 (75)	99 (63)
Support groups and other resources for colorectal cancer survivors	100 (64)	105 (67)

Values provided as n (%). Total number of respondents does not always equal 156 due to missing data.

*Adapted from Institute of Medicine Report.¹

also lacked information about patients' practical concerns, including financial, legal, and transportation issues (11 comments).

Preference for Format

Of respondents, 83% reported that a printed survivorship care plan would be acceptable, a higher percentage than those who reported that receiving this information via web site, E-mail, or conversation with the oncology provider would be acceptable (Table 4). In response to open-ended questions about additional acceptable formats for survivorship care plans, 19 respondents volunteered that they would prefer the information in an electronic document that

would become integrated into the electronic medical record.

Past Receipt and Usefulness

Although the vast majority of respondents reported having ever received a summary of diagnosis or a summary of treatment for their patients who completed treatment for CRC (86% and 89%, respectively), a minority reported having ever received recommendations for ongoing primary care or information about what aspects of care the PCP and oncology provider are responsible for (30% and 20%, respectively) (Table 5). Across these categories (summary of diagnosis, summary of treatment, recommendations for ongoing primary care, what aspects of care the PCP and oncology provider are responsible for), more than three quarters of those who had ever received information within each category found it useful (77%–81%), and almost all respondents who never received this information reported that they would find it useful (96%–100%). Nearly all respondents would like to receive a summary of the diagnosis (100%), a summary of treatment (99%), recommendations for ongoing care the patient should receive from the PCP (96%), and information from the patient's cancer care provider about what aspects of care after treatment the PCP and the cancer care provider are each responsible for (97%).

Table 4. Preferences for Format and Delivery of Survivorship Care Plan

	Participants Who Would Like This
Format	
Printed document	129 (83)
Website	39 (25)
E-mail	44 (28)
Conversation with cancer care provider	50 (32)
Delivery	
From the patient at an office visit	32 (21)
Directly from the cancer care provider's office	153 (98)

Values provided as n (%). Percentages do not add to 100 because respondents could select multiple formats or styles of delivery.

Table 5. Primary Care Physicians' Perspectives Regarding Receipt and Usefulness of Information about Colorectal Cancer Survivors

Component of Survivorship Care Plan	N	Ever Received Component (Yes)	Component Was Extremely Useful*	Component Was Somewhat Useful*
Summary of diagnosis	156	130 (86)	99 (76)	30 (23)
Summary of treatment	155	133 (86)	102 (77)	30 (23)
Recommendations for ongoing primary care	156	45 (29)	36 (80)	9 (20)
Information on what aspects of care PCP and cancer care providers are responsible for	156	31 (20)	25 (81)	6 (19)

Values provided as n (%).

*Of those who ever did receive the component.

Discussion

We identified informational needs of PCPs who care for CRC survivors. When presented with 45 topics included in survivorship care plans, PCPs generally found them important but lacking when caring for CRC survivors. More than three quarters of the topics were deemed very important by at least half of participants, and few topics were deemed unimportant, suggesting that the IOM framework includes information that is critical to PCPs.

In survey studies of PCPs, PCPs typically have reported some discomfort when taking on the care of cancer survivors, either in the capacity of shared care with oncology providers or as sole providers of care after treatment.^{11–14} This may result from limited communication with oncology providers about patients' treatment.¹³ Our study found that providers rarely had complete information about CRC survivors' diagnosis and treatment, a problem that PCPs have reported in other studies (although sometimes to a lesser degree).^{11,15} Furthermore, most providers in our study valued communication regarding which specialty should assume responsibility for specific aspects of treatment, but only one-fifth ever received information delineating specific aspects of care between the PCP and the oncology provider.

PCPs previously have noted a lack of training about survivorship issues.¹¹ Providers in our study reported a need for information about multiple facets of CRC follow-up. Although guidelines for CRC survivorship care are put forth by both the American Society of Clinical Oncology and the National Comprehensive Cancer Network, they are limited in scope, focusing on monitoring for recurrences and second CRCs and not on addressing medical and

psychological late effects.^{16,17} They also are not directly disseminated to PCPs, who may not keep abreast of cancer society guidelines. Indeed, previous studies of PCPs have found limited awareness of guidelines and other information to inform follow-up care for cancer survivors.^{11,13}

The use of survivorship care plans may ameliorate both poor communication and limited dissemination of survivorship information. Although survivorship care plans were proposed in 2006, fewer than a third of study participants ever received written recommendations for ongoing care, and fewer than a quarter ever received information about what aspects of care PCP and cancer care providers are responsible for. These are key elements of survivorship care plans, and our study demonstrates a critical gap between the IOM recommendations and the actual practice of survivorship care. This gap has been described elsewhere, and implementation of survivorship care plans lags behind recommendations.¹⁸

Respondents who received written recommendations for ongoing care and descriptions of responsibilities of each provider generally found this information useful. Furthermore, explicit coordination of care with regard to monitoring for CRC recurrence was deemed very important by 98% of respondents. Of those who never received information in survivorship care plans, nearly all reported that it would be useful. Previous studies have found that PCPs are receptive to survivorship care plans as tools to improve coordinated care for cancer survivors.^{11–12,15,18–20}

Notably, a small proportion of providers in our study reported that the name and dose of chemotherapy drugs and the dose of radiation were very important, although a substantial proportion of respondents (41%–46%) felt they did not have enough information about these topics. This discrepancy may be

explained by at least half of respondents finding these topics at least somewhat important (data not shown). These treatment details may be the most relevant risk factors predicting the occurrence of important late effects. However, reporting treatment may be the most burdensome part of completing a survivorship care plan. A simplified strategy for presenting information in survivorship care plans would entail limiting the presentation of treatment details (which PCPs find less important than other information) but providing clear guidance about how to prevent, detect, and manage the late effects of treatment.

Our study had a limited response rate, although it is similar to the response rate (37%) achieved in a similar Internet-based survey of providers within PBRNs.²¹ In that study, an option of a mailed, paper-based survey improved response rates, but we opted to limit our survey to Internet-based administration to reduce network and clinician burden. It is possible that those who did not respond to our Internet-based survey but would have responded to a paper-based survey have different informational preferences, especially regarding the format when receiving information, than our sample. More generally, it also is possible that our sample participants were more interested than nonresponders in the challenges of caring for CRC survivors or felt a stronger need for information, potentially biasing our results toward demonstrating greater informational needs. The widespread agreement across issues raised in this study suggests that, even if there were a bias, a pattern of strong needs and preferences for information would remain. This study was not powered to identify predictors of preferences for information, which may vary by provider characteristics, such as experience with CRC survivors. This survey relied on providers to recall their experiences and report estimates, and we were unable to verify responses. The characteristics of the PCPs at the 3 sites chosen for this study may not be generalizable to all PCPs. However, we have no reason to believe that participants were more or less informed about CRC or interested in receiving survivorship information than PCPs elsewhere.

Our study focused on the use of survivorship care plans as static documents communicating information from the oncologist to the PCP, as described in the IOM report.¹ However, coordination may be enhanced with the use of dynamic survivorship care

plans that oncologists update over the course of treatment and follow-up, thereby keeping PCPs informed while the patient is under the oncologist's care.^{22,23} At the same time, PCPs may wish to inform the oncologist about changes in the survivor's health status, the provision of testing, or other general preventive measures. Future studies should examine whether a dynamic survivorship care plan would be useful and feasible for PCPs, CRC survivors, and oncologists.

This is the first published study of which we are aware that assesses the potential usefulness to PCPs of the IOM framework for survivorship care plans for CRC survivors. Our sample of PCPs, which includes physicians and nonphysician providers in academic and community settings in multiple distinct locations, represents a wide array of practitioners. Despite this diversity, there is widespread agreement that providers would appreciate and use the information in the IOM framework. There are deficiencies in communication about survivors' treatment history and specific gaps in knowledge about CRC survivorship, both of which should be addressed in survivorship care plans created for CRC survivors.

Conclusions

Findings from this study suggest that PCPs want comprehensive CRC survivorship information, but before calling for the development of lengthy CRC survivorship care plans, further research with oncologists must assess whether creating such detailed documents is feasible and deemed an important use of clinical resources. Our study still provides a strong evidence base for the creation of a CRC survivorship care plan that responds to the needs of PCPs. The development of a new CRC survivorship care plan will provide a basis for future research evaluating whether survivorship care plan use resolves deficiencies in care for CRC survivors. Specifically, studies need to address whether survivorship care plans facilitate coordination of care, improve quality of care, and help PCPs feel more comfortable in providing care to CRC survivors.

References

1. Hewitt M, Greenfield S, Stovall E. From cancer patient to cancer survivor: lost in transition. Washington, D.C.: Institute of Medicine and National

- Research Council; 2005. Available from: <http://www.nap.edu/openbook.php?isbn=0309095956>.
2. Centers for Disease Control and Prevention (CDC). Cancer survivors—United States, 2007. *MMWR Morb Mortal Wkly Rep*. 2011;60:269–72.
 3. American Cancer Society. Cancer facts and figures 2010. Available from: <http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.pdf>. Accessed July 12, 2012.
 4. Deimling GT, Bowman KF, Sterns S, Wagner LJ, Kahana B. Cancer-related health worries and psychological distress among older adult, long-term cancer survivors. *Psychooncology* 2006;15:306–20.
 5. Denlinger C, Barsevick A. The challenges of colorectal cancer survivorship. *J Natl Compr Canc Netw* 2009;7:883–93.
 6. Harrison SE, Watson EK, Ward AM, et al. Primary health and supportive care needs of long-term cancer survivors: a questionnaire survey. *J Clin Oncol* 2011;29:2091–8.
 7. Schneider EC, Malin JL, Kahn KL, Ko CY, Adams J, Epstein AM. Surviving colorectal cancer: patient-reported symptoms 4 years after diagnosis. *Cancer* 2007;110:2075–82.
 8. Earle CC, Neville BA. Under use of necessary care among cancer survivors. *Cancer* 2004;101:1712–9.
 9. Snyder CF, Earle CC, Herbert RJ, Neville BA, Blackford AL, Frick KD. Preventive care for colorectal cancer survivors: a 5-year longitudinal study. *J Clin Oncol* 2008;26:1073–9.
 10. Snyder CF, Earle CC, Herbert RJ, Neville BA, Blackford AL, Frick KD. Trends in follow-up and preventive care for colorectal cancer survivors. *J Gen Intern Med* 2008;23:254–9.
 11. Bober SL, Recklitis CJ, Campbell EG, et al. Caring for cancer survivors: a survey of primary care physicians. *Cancer* 2009;115(Suppl 18):4409–18.
 12. Del Giudice ME, Grunfeld E, Harvey BJ, Piliotis E, Verma S. Primary care physicians' views of routine follow-up care of cancer survivors. *J Clin Oncol* 2009;27:3338–45.
 13. Nissen MJ, Beran MS, Lee MW, Mehta SR, Pine DA, Swenson KK. Views of primary care providers on follow-up care of cancer patients. *Fam Med* 2007;39:477–82.
 14. Potosky AL, Han PK, Rowland J, et al. Differences between primary care physicians' and oncologists' knowledge, attitudes and practices regarding the care of cancer survivors. *J Gen Intern Med* 2011;26:1403–10.
 15. Baravelli C, Krishnasamy M, Pezaro C, et al. The views of bowel cancer survivors and health care professionals regarding survivorship care plans and post treatment follow up. *J Cancer Surviv* 2009;3:99–108.
 16. National Comprehensive Cancer Network . NCCN guidelines: NCCN Guidelines for detection, prevention, and risk reduction. Colorectal cancer screening. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#detection. Accessed July 12, 2012.
 17. Benson AB 3rd, Desch CE, Flynn PJ, et al. 2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. *J Clin Oncol* 2000;18:3586–8.
 18. Salz T, Oeffinger K, McCabe M, Layne T, Bach P. Survivorship care plans in research and practice. *CA Cancer J Clin* 2012 Jan 12. Doi:10.3322/caac.20142. [Epub ahead of print].
 19. Hewitt ME, Bamundo A, Day R, Harvey C. Perspectives on post-treatment cancer care: qualitative research with survivors, nurses, and physicians. *J Clin Oncol* 2007;25:2270–3.
 20. Shalom MM, Hahn EE, Casillas J, Ganz PA. Do Survivorship care plans make a difference? A primary care provider perspective. *J Oncol Pract* 2011;7:314–8.
 21. Kroth PJ, McPherson L, Leverage R, et al. Combining web-based and mail surveys improves response rates: a PBRN study from PRIME Net. *Ann Fam Med*. 2009;7:245–8.
 22. Earle CC. Failing to plan is planning to fail: improving the quality of care with survivorship care plans. *J Clin Oncol* 2006;24:5112–6.
 23. Horning SJ. Follow-up of adult cancer survivors: new paradigms for survivorship care planning. *Hematol Oncol Clin North Am* 2008;22:201–10, v.

Appendix: Survey

Please note that the online version of this survey did not include question numbers. In the online version, skip patterns for the survey were automated; in this Appendix they are noted in brackets.

Primary Care of Colorectal Cancer Survivors

Thank you for agreeing to participate in our survey about the information primary care providers receive—and would like to receive—about the cancer survivors they care for in their clinical practice. We hope the information from this survey will improve communication about cancer care for cancer survivors. The survey should take about 10 to 15 minutes to complete.

As a thank you for your participation, you will receive a \$50 Amazon.com Gift Card via E-mail. When you are done, you will be asked to provide an E-mail address so that we can E-mail you the electronic gift certificate. You will receive your electronic gift certificate within 30 minutes. Please note: Your Amazon.com Gift Card will be in an email from <name>, with the email ad-

dress <email address>. If your email account uses a spam trap, either check you spam trap for this email or add this email address to you list of safe senders.

You may skip any questions you do not feel comfortable answering. Your responses will remain anonymous. When you finish the survey, your survey responses and a unique study ID will be sent electronically to our study team at Memorial Sloan-Kettering Cancer Center. We will not have access to your name, your clinical practice, or your work email address. The email address you provide at the end of this survey (for payment purposes) can be any email address you choose – you can use a personal email account or a work email account. This email address will not be associated with your responses to the survey. This is to ensure your privacy.

If you have any questions about this survey, please call <PI> at <phone>.

Please answer the following questions to see if you are eligible for the study.

1. Do you provide primary care in your practice?
 Yes
 No [*Sorry, you are not eligible to participate in this survey. Thank you for your time and interest.*]
2. During the last year, did you see any patients in your practice who had completed therapy for colon or rectal cancer at any point in their lives?
 Yes
 No [*Sorry, you are not eligible to participate in this survey. Thank you for your time and interest.*]
 Don't remember [*Sorry, you are not eligible to participate in this survey. Thank you for your time and interest.*]

You are eligible for the survey. These first few questions are about your medical practice and your patients.

3. What is your profession?
 Physician [*Go to question 4.*]
 Nurse Practitioner [*Go to question 6.*]
 Physician assistant [*Go to question 7.*]
4. Are you board certified in any of the following specialties?

- Internal Medicine
- Geriatrics
- Family practice
- A medical subspecialty (please list): _____

5. In what year did you graduate from medical school?

_____ [*Go to question 8.*]

6. In what year did you complete your nurse practitioner training?

_____ [*Go to question 8.*]

7. In what year did you complete your physician assistant training?

_____ [*Go to question 8.*]

8. How old are you?

9. What is your gender?

- Male
- Female

10. How many practitioners (MD, DO, NP, or PA) are in your office?

11. In what zip code is your practice is located?

12. Does your practice use electronic health records?

- Yes
- No

13. Are there any oncologists or cancer specialists in your practice?

- Yes
- No
- Don't know

14. During the last 12 months, how many patients who were **currently undergoing**

treatment for any kind of cancer do you estimate that you cared for in your practice? Please count any patients who were undergoing cancer treatment for **any part** of the last 12 months.

15. How many of these patients had been diagnosed with **colorectal cancer**?

_____ [If 0 patients, “Sorry, you are not eligible to participate in this survey. Thank you for your time and interest.”]

16. During the last 12 months, how many individual patients who **had completed active treatment** for any kind of cancer do you estimate that you cared for in your practice? Please count any patients who had completed cancer treatment any time **during or before** the last 12 months.

17. How many of these patients had been diagnosed with **colorectal cancer**?

18. Please think about your patients who have completed treatment for any kind of cancer and *do not* have active disease. For what percentage of these patients do you feel you have **enough information** to provide the best general medical care (for example, screening and health maintenance) for them?

_____ %

The following questions are about the information you receive about your patients who have completed treatment for *colon or rectal cancer* and do not have active disease. We will ask you *how important* it is for you to have information about these patients *and how much information* you usually get about them.

There will be questions about 6 topics of medical information you get about your patients.

Topic 1: Diagnosis Summary

When you see patients who have completed treatment for colon or rectal cancer and do not have active disease, **how important is it for you to know:**

	Not Important	Somewhat Important	Very Important	Undecided
19. ... the method of diagnosis	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
20. ... where the patient received treatment	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
21. ... the site of the patient’s disease (colon or rectum)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
22. ... the stage of the patient’s disease	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
23. ... the grade of the patient’s disease	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
24. ... the relevant pathology of the patient’s disease	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

When you see patients who have completed treatment for colon or rectal cancer and do not have active disease, **how much information do you typically have about:**

	Not Enough	Just the Right Amount	Too Much	It Varies Too Much To Say
25. ... the method of diagnosis	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
26. ... where the patient received treatment	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
27. ... the site of the patient’s disease (colon or rectum)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
28. ... the stage of the patient’s disease	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
29. ... the grade of the patient’s disease	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
30. ... the relevant pathology of the patient’s disease	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Topic 2: Surgery

When you see patients who have completed treatment for colon or rectal cancer and do not have active disease, **how important is it for you to know:**

	Not Important	Somewhat Important	Very Important	Undecided
31. ... whether the patient had surgery	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
32. ... the date of the patient's surgery	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
33. ... whether there were surgical complications	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
34. ... what the patient's anatomy is after surgery	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
35. ... whether there are lingering effects of surgery	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

When you see patients who have completed treatment for colon or rectal cancer and do not have active disease, **how much information do you typically have about:**

	Not Enough	Just the Right Amount	Too Much	It Varies Too Much To Say
36. ... whether the patient had surgery	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
37. ... the date of the patient's surgery	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
38. ... if there were surgical complications	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
39. ... what the patient's anatomy is after surgery	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
40. ... whether there are lingering effects of surgery	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Topic 3: Chemotherapy

When you see patients who have completed treatment for colon or rectal cancer and do not have active disease, **how important is it for you to know:**

	Not Important	Somewhat Important	Very Important	Undecided
41. ... whether the patient had chemotherapy	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
42. ... the dates each regimen of chemotherapy was completed	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
43. ... the name of each chemotherapy drug administered	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
44. ... the dose of each chemotherapy drug administered	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
45. ... the possible long-term risks and complications from chemotherapy	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
46. ... the contact information for the doctor who administered chemotherapy	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
47. ... the reason for terminating chemotherapy	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
48. ... whether there were problems with chemotherapy	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

When you see patients who have completed treatment for colon or rectal cancer and do not have active disease, **how much information do you typically have about:**

	Not Enough	Just the Right Amount	Too Much	It Varies Too Much To Say
49. ... whether the patient had chemotherapy	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
50. ... the dates each regimen of chemotherapy was completed	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
51. ... the name of each chemotherapy drug administered	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
52. ... the dose of each chemotherapy drug administered	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
53. ... the possible long-term risks and complications from chemotherapy	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
54. ... the contact information for the doctor who administered chemotherapy	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
55. ... the reason for terminating chemotherapy	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
56. ... whether there were problems with chemotherapy	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Topic 4: Radiation Therapy

When you see patients who have completed treatment for colon or rectal cancer and do not have active disease, **how important is it for you to know:**

	Not Important	Somewhat Important	Very Important	Undecided
57. ... whether the patient had radiation therapy	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
58. ... the date radiation therapy was completed	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
59. ... the location where radiation was administered	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
60. ... the dose of radiation	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
61. ... the contact information for the doctor who administered radiation therapy	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
62. ... the possible long-term risks and complications from radiation therapy	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
63. ... the reason for terminating radiation therapy	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
64. ... whether there were problems with radiation therapy	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

When you see patients who have completed treatment for colon or rectal cancer and do not have active disease, **how much information do you typically have about:**

	Not Enough	Just the Right Amount	Too Much	It Varies Too Much To Say
65. ... whether the patient had radiation therapy	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
66. ... the date radiation therapy was completed	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
67. ... the location where radiation was administered	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
68. ... the dose of radiation	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
69. ... the contact information for the doctor who administered radiation therapy	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
70. ... the possible long-term risks and complications from radiation therapy	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
71. ... the reason for terminating radiation therapy	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
72. ... whether there were problems with radiation therapy	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Topic 5: Other Aspects of Treatment

When you see patients who have completed treatment for colon or rectal cancer and do not have active disease, **how important is it for you to know:**

	Not Important	Somewhat Important	Very Important	Undecided
73. ... whether the patient was in a clinical trial	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
74. ... if the patient was hospitalized for complications during treatment	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
75. ... whether psychosocial services were provided during treatment	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
76. ... whether nutritional services were provided during treatment	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
77. ... whether other supportive services were provided during treatment	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

When you see patients who have completed treatment for colon or rectal cancer and do not have active disease, **how much information do you typically have about:**

	Not Enough	Just the Right Amount	Too Much	It Varies Too Much To Say
78. ... whether the patient was in a clinical trial	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
79. ... whether the patient was hospitalized for complications during treatment	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
80. ... whether psychosocial services were provided during treatment	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
81. ... whether nutritional services were provided during treatment	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
82. ... whether other supportive services were provided during treatment	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Topic 6: Continuity of Care

When you see patients who have completed treatment for colon or rectal cancer and do not have active disease, **how important is it for you to know:**

	Not Important	Somewhat Important	Very Important	Undecided
83. ... whether the cancer care provider(s) intend(s) to monitor the patient for recurrence and second primaries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
84. ... whether the cancer care provider(s) intend(s) to monitor the patient for cancers at other sites	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

When you see patients who have completed treatment for colon or rectal cancer and do not have active disease, **how much information do you typically have about:**

	Not Enough	Just the Right Amount	Too Much	It Varies Too Much To Say
83. ... whether the cancer care provider(s) intend(s) to monitor the patient for recurrence and second primaries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
84. ... whether the cancer care provider(s) intend(s) to monitor the patient for cancers at other sites	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Please tell us about any other topics that are important to you that we did not ask about. These topics can be about diagnosis, surgery, chemotherapy, radiation therapy, other aspects of treatment, continuity of care, or any other aspect of patient care.

When you see patients who have completed treatment for colon or rectal cancer and do not have active disease, **how much information do you typically have about this topic?**

Please list any topics that are important to you below	Not Enough	Just the Right Amount	Too Much	It Varies Too Much To Say
85. _____	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
86. _____	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
87. _____	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
88. _____	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
89. _____	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

This set of questions is about information you receive about your patients who have had colon or rectal cancer.

Topic 7: Medical Reports

When you see patients who have completed treatment for colon or rectal cancer and do NOT have active disease, **how important is it for you to have:**

	Not Important	Somewhat Important	Very Important	Undecided
90. ... the operative report	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
91. ... the pathology report	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

When you see patients who have completed treatment for colon or rectal cancer and do NOT have active disease, **how much information do you typically have about:**

	Not Enough	Just the Right Amount	Too Much	It Varies Too Much To Say
92. ... the operative report	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
93. ... the pathology report	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

This set of questions is about general knowledge about treating patients who have had colon or rectal cancer.

Topic 8: General Knowledge

For patients who have completed treatment for colon or rectal cancer and do not have active disease, **how important is it for you to know about:**

	Not Important	Somewhat Important	Very Important	Undecided
94. ... the schedule of recommended colorectal cancer surveillance	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
95. ... the schedule of recommended screening for noncolorectal cancers	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
96. ... any increased risks for second colorectal cancers, other cancer, and other diseases	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
97. ... possible signs of recurrence and second tumors	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
98. ... possible effects of cancer on marital/partner relationship, sexual functioning, work, parenting, and future needs for psychosocial support	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
99. ... genetic counseling and testing to identify high-risk individuals who could benefit from more comprehensive cancer surveillance	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
100. ... chemoprevention strategies for secondary prevention (eg, tamoxifen in women at high risk for breast cancer)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
101. ... other types of follow-up care providers that may be needed (eg, rehabilitation, fertility, psychology)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
102. ... support groups and other resources for colorectal cancer survivors	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

For patients who have completed treatment for colon or rectal cancer and do not have active disease, **how much do you know about:**

	Not Enough	Enough	It Varies Too Much To Say
103. ... the schedule of recommended colorectal cancer surveillance	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
104. ... the schedule of recommended screening for noncolorectal cancers	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
105. ... any increased risks for second colorectal cancers, other cancer, and other diseases	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
106. ... possible signs of recurrence and second tumors	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
107. ... possible effects of cancer on marital/partner relationship, sexual functioning, work, parenting, and future needs for psychosocial support	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
108. ... genetic counseling and testing to identify high-risk individuals who could benefit from more comprehensive cancer surveillance	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
109. ... chemoprevention strategies for secondary prevention (eg, tamoxifen in women at high risk for breast cancer)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
110. ... other types of follow-up care providers that may be needed (eg, rehabilitation, fertility, psychology)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
111. ... support groups and other resources for colorectal cancer survivors	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Please tell us about any other area of general knowledge that is important to you that we did not ask about. These topics can be about any aspect of care for patients who have completed treatment for colon or rectal cancer.

Please list below any areas of knowledge that are important to you:	How much do you know about this area?		
	Not Enough	Enough	It Varies Too Much To Say
112. _____	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
113. _____	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
114. _____	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
115. _____	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
116. _____	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

The following questions are about written information you received about your patients who have had **colon or rectal cancer**. There are 4 topics of written information.

Topic 1: Diagnosis Summary

117. Have you ever received a report from a cancer care provider summarizing a patient's cancer diagnosis?
- Yes [Go to question 118.]
 - No [Go to question 119.]
 - Don't remember [Go to question 119.]
118. How useful was it?
- Extremely useful
 - Somewhat useful
 - Not useful at all
 - Don't remember
119. Would you like to receive a summary report of the cancer diagnosis for each patient?
- Yes
 - Not sure
 - No

Topic 2: Treatment Summary

120. Have you ever received a report from a cancer care provider summarizing a patient's cancer treatment (such as surgery, chemotherapy, or radiation)?
- Yes [Go to question 121.]
 - No [Go to question 122.]
 - Don't remember [Go to question 122.]
121. How useful was it?
- Extremely useful
 - Somewhat useful
 - Not useful at all
 - Don't remember
122. Would you like to receive a summary report of the cancer treatment for each patient?
- Yes
 - Not sure
 - No

Topic 3: Recommendations for Ongoing Care

123. Have you ever received a summary of the ongoing care the patient should receive from their primary care provider?
- Yes [Go to question 124.]
 - No [Go to question 125.]
 - Don't remember [Go to question 125.]
124. How useful was it?
- Extremely useful
 - Somewhat useful
 - Not useful at all
 - Don't remember
125. Would you like to receive a summary of recommended ongoing care for each patient?
- Yes
 - Not sure
 - No

Topic 4: Written Information about Responsibilities for Care After Treatment

126. Have you ever received written information from a patient's cancer care provider about what aspects of post-treatment care you and the cancer care provider are each responsible for?
- Yes [Go to question 127.]
 - No [Go to question 128.]
 - Don't remember [Go to question 128.]
127. How useful was it?
- Extremely useful
 - Somewhat useful
 - Not useful at all
 - Don't remember
128. Would you like to have a written information from each patient's cancer care provider about what aspects of posttreatment care you and the cancer care provider are each responsible for?
- Yes
 - Not sure
 - No

You indicated that you would like to receive some information about the diagnosis, treatment, or recommended care for each patient who finished active treatment for cancer.

The following questions are about your preferences for receiving this information about diagnosis, treatment, or recommended ongoing care for your patients who have completed treatment for **any kind** of cancer.

129. If you were to receive this information, what format would be most useful to you? (Please check all that apply.)

- A printed document
- A link to a web site
- An E-mail
- A conversation with the cancer care provider
- Other (please describe) _____

130. How would you like to receive this information? (Please check all that apply.)

- From the patient at an office visit
- Directly from the cancer care provider's office
- Other (please describe) _____

Thank you for your participation! Please enter your email address below so that we can email you a \$50 gift certificate to Amazon.com. You will receive your gift certificate in an email from <name redacted>.

131. E-mail address: _____

132. Please verify E-mail address: _____

Note: you do not need to use the same E-mail address to which your invitation was mailed. Please make sure you can receive eE-mail at the address you entered above. Your Amazon.com gift card will be in an eE-mail from <name redacted>, with the E-mail address <address redacted>. If your E-mail account uses a spam trap, either check you spam trap for this E-mail or add this E-mail address to your list of safe senders.

Thanks for taking the survey. We hope this will help us take better care of our patients. Please click on the logout button.